AKD Research reports that Pakistan’s pharmaceutical sector’s profitability fell 11.5% YoY to PKR 7.5bn in 2QCY26, down from PKR 8.5bn last year. The drop was driven by stagnant volumes, weaker consumer demand, higher operating costs, and a steeper tax rate of 50% versus 42% previously.
Despite this, gross margins improved to 42.8% (up 241bps YoY) on higher prices, stable currency, and a stronger mix of high-margin products. Revenue rose 2.8% YoY to PKR 89bn, though Afghan border closures limited export volumes.
Company performance varied:
- HPL, ABOT, and HALEON posted stronger earnings, aided by margin expansion and higher other income.
- HINOON and GLAXO saw profits fall due to higher opex and tax pressures.
- SEARL widened losses to PKR 1.8bn, weighed down by surging admin costs and deferred tax charges.
Cumulatively, sector profitability rose 6% YoY in 1HCY26, supported by stronger volumes in 1QCY26.
Outlook: AKD Research remains positive, citing pricing flexibility, new launches, stable currency, and recovering demand. Risks include rising API and energy costs amid Middle East tensions and continued Afghan border closure. Preferred picks are GLAXO, HALEON, and HINOON for their strong brand equity, portfolio mix, and export potential.